Posted by Michael Wonder on 17 Aug 2020
G1 Therapeutics announces acceptance and priority review of NDA for trilaciclib for patients with small cell lung cancer
17 August 2020 - G1 launching expanded access program for patients with small cell lung cancer in the U.S..
G1 Therapeutics today announced that the U.S. FDA has accepted the new drug application for trilaciclib for small cell lung cancer patients being treated with chemotherapy and granted Priority Review with a Prescription Drug User Fee Act action date of 15 February 2021.
Trilaciclib is a first-in-class investigational therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes.
